PL2203433T3 - 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy - Google Patents
5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycyInfo
- Publication number
- PL2203433T3 PL2203433T3 PL08832210T PL08832210T PL2203433T3 PL 2203433 T3 PL2203433 T3 PL 2203433T3 PL 08832210 T PL08832210 T PL 08832210T PL 08832210 T PL08832210 T PL 08832210T PL 2203433 T3 PL2203433 T3 PL 2203433T3
- Authority
- PL
- Poland
- Prior art keywords
- oxoethoxy
- thiazolidine
- dione
- methoxyphenyl
- benzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97263907P | 2007-09-14 | 2007-09-14 | |
| PCT/US2008/010723 WO2009038681A1 (en) | 2007-09-14 | 2008-09-15 | Thiazolidinedione analogues for the treatment of hypertension |
| EP08832210A EP2203433B1 (en) | 2007-09-14 | 2008-09-15 | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2203433T3 true PL2203433T3 (pl) | 2013-04-30 |
Family
ID=40239575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08832210T PL2203433T3 (pl) | 2007-09-14 | 2008-09-15 | 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8067450B2 (pl) |
| EP (1) | EP2203433B1 (pl) |
| JP (1) | JP5371988B2 (pl) |
| KR (1) | KR101537830B1 (pl) |
| CN (1) | CN101848901B (pl) |
| AU (1) | AU2008301905B2 (pl) |
| BR (1) | BRPI0817096B8 (pl) |
| CA (1) | CA2699289C (pl) |
| ES (1) | ES2398313T3 (pl) |
| HK (1) | HK1146484A1 (pl) |
| IL (1) | IL204440A (pl) |
| MX (1) | MX2010002820A (pl) |
| NZ (2) | NZ597381A (pl) |
| PL (1) | PL2203433T3 (pl) |
| RU (1) | RU2486179C2 (pl) |
| WO (1) | WO2009038681A1 (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2646149A1 (en) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
| CN101454005B (zh) | 2006-03-16 | 2013-01-02 | 新陈代谢解决方案开发公司 | 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物 |
| US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
| EP2203433B1 (en) | 2007-09-14 | 2012-10-31 | Metabolic Solutions Development Company LLC | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| WO2010105048A1 (en) * | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
| AU2010340058A1 (en) * | 2009-12-15 | 2012-06-21 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases |
| AU2014202074B2 (en) * | 2009-12-15 | 2016-01-07 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| EP2512475A1 (en) * | 2009-12-15 | 2012-10-24 | Metabolic Solutions Development Company LLC | Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases |
| PL2513070T3 (pl) * | 2009-12-15 | 2018-05-30 | Cirius Therapeutics, Inc. | Oszczędzające ppar sole tiazolidynodionu do leczenia chorób metabolicznych |
| RU2570424C2 (ru) * | 2009-12-15 | 2015-12-10 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Рапп-поддерживающие тиазолидиндионы и их комбинации для лечения нейродегенеративных заболеваний |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| MX2012012092A (es) | 2010-04-19 | 2012-12-17 | Metabolic Solutions Dev Co Llc | Sintesis novedosa para compuestos de tiazolidinadiona. |
| RU2012149458A (ru) * | 2010-04-21 | 2014-05-27 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Аналогии тиазолидиндиона |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2603498B1 (en) * | 2010-08-10 | 2016-11-09 | Octeta Therapeutics, LLC | Novel synthesis for thiazolidinedione compounds |
| NZ606597A (en) | 2010-08-10 | 2014-12-24 | Metabolic Solutions Dev Co Llc | Synthesis for thiazolidinedione compounds |
| WO2012109495A1 (en) * | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012149083A1 (en) * | 2011-04-28 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones for the treatment of kidney related diseases |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
| CA2941562C (en) * | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| MX2016000724A (es) | 2013-07-22 | 2016-04-13 | Metabolic Solutions Dev Co Llc | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EP3749292A1 (en) | 2018-02-08 | 2020-12-16 | ENYO Pharma | Use of modulators of neet proteins for the treatment of infection |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| WO1986002073A1 (en) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
| US5356913A (en) | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| AU1743292A (en) | 1991-04-11 | 1992-11-17 | Takeda Chemical Industries Ltd. | Thiazolidinedione derivatives, production and use thereof |
| NO302471B1 (no) * | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| CZ289317B6 (cs) * | 1994-04-11 | 2002-01-16 | Sankyo Company Limited | Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| RU2158607C2 (ru) | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Лечение артериосклероза и ксантомы |
| EP1210087A2 (en) | 1999-04-29 | 2002-06-05 | City of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| IL147308A0 (en) | 1999-06-30 | 2002-08-14 | Tularik Inc | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| EE200300519A (et) | 2001-04-26 | 2004-02-16 | L�civa, a.s. | Meetod pioglitasooni kui suhkurtõvevastase aine saamiseks |
| WO2003026586A2 (en) | 2001-09-28 | 2003-04-03 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
| EP1521753B1 (en) | 2002-07-16 | 2007-09-05 | Cadila Healthcare Ltd. | A process to prepare pioglitazone via several intermediates. |
| EP1607103A1 (en) * | 2003-03-20 | 2005-12-21 | Eisai Co., Ltd. | Concomitant drug as therapeutic agent for inflammatory bowel disease |
| US7230016B2 (en) | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| JP2005015477A (ja) * | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| US20070078170A1 (en) | 2003-08-28 | 2007-04-05 | Khanduri Chandra H | Process for the preparation of pioglitazone |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| US7777038B2 (en) | 2004-09-28 | 2010-08-17 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compound |
| CN101454005B (zh) | 2006-03-16 | 2013-01-02 | 新陈代谢解决方案开发公司 | 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物 |
| CA2646170A1 (en) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |
| CA2646149A1 (en) * | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids |
| EP2203433B1 (en) | 2007-09-14 | 2012-10-31 | Metabolic Solutions Development Company LLC | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes |
| WO2010105048A1 (en) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
-
2008
- 2008-09-15 EP EP08832210A patent/EP2203433B1/en active Active
- 2008-09-15 PL PL08832210T patent/PL2203433T3/pl unknown
- 2008-09-15 KR KR1020107008064A patent/KR101537830B1/ko active IP Right Grant
- 2008-09-15 JP JP2010524882A patent/JP5371988B2/ja active Active
- 2008-09-15 WO PCT/US2008/010723 patent/WO2009038681A1/en active Application Filing
- 2008-09-15 MX MX2010002820A patent/MX2010002820A/es active IP Right Grant
- 2008-09-15 NZ NZ597381A patent/NZ597381A/xx unknown
- 2008-09-15 CA CA2699289A patent/CA2699289C/en active Active
- 2008-09-15 RU RU2010114727/04A patent/RU2486179C2/ru active
- 2008-09-15 NZ NZ583889A patent/NZ583889A/en unknown
- 2008-09-15 BR BRPI0817096A patent/BRPI0817096B8/pt active IP Right Grant
- 2008-09-15 ES ES08832210T patent/ES2398313T3/es active Active
- 2008-09-15 US US12/677,541 patent/US8067450B2/en active Active
- 2008-09-15 AU AU2008301905A patent/AU2008301905B2/en active Active
- 2008-09-15 CN CN2008801147383A patent/CN101848901B/zh active Active
-
2010
- 2010-03-11 IL IL204440A patent/IL204440A/en active IP Right Grant
-
2011
- 2011-01-21 HK HK11100608.1A patent/HK1146484A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817096B1 (pt) | 2020-11-10 |
| NZ597381A (en) | 2013-03-28 |
| CA2699289C (en) | 2016-01-19 |
| RU2486179C2 (ru) | 2013-06-27 |
| AU2008301905B2 (en) | 2013-06-27 |
| BRPI0817096A2 (pt) | 2017-05-02 |
| CA2699289A1 (en) | 2009-03-26 |
| CN101848901A (zh) | 2010-09-29 |
| EP2203433A1 (en) | 2010-07-07 |
| AU2008301905A1 (en) | 2009-03-26 |
| JP2010539171A (ja) | 2010-12-16 |
| KR20100075915A (ko) | 2010-07-05 |
| IL204440A (en) | 2013-05-30 |
| NZ583889A (en) | 2012-01-12 |
| WO2009038681A1 (en) | 2009-03-26 |
| US8067450B2 (en) | 2011-11-29 |
| ES2398313T3 (es) | 2013-03-15 |
| MX2010002820A (es) | 2010-04-01 |
| BRPI0817096A8 (pt) | 2017-10-10 |
| BRPI0817096B8 (pt) | 2021-05-25 |
| JP5371988B2 (ja) | 2013-12-18 |
| EP2203433B1 (en) | 2012-10-31 |
| US20100222399A1 (en) | 2010-09-02 |
| CN101848901B (zh) | 2012-11-21 |
| RU2010114727A (ru) | 2011-10-20 |
| HK1146484A1 (en) | 2011-06-10 |
| KR101537830B1 (ko) | 2015-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2203433T3 (pl) | 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy | |
| HRP20180667T1 (hr) | Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin | |
| BRPI0814294A2 (pt) | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. | |
| IL236883A0 (en) | Intermediate compounds for the preparation of (1-(s))-n-(s-cyclohexyl-2-{(4)-2-(s-(fluoro-benzoyl)-thiazol-2-yl]pyrrolidine-1-yl}-2 -oxo-ethyl)-2-methylamino-propionamide | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| IL205742A0 (en) | 4-(4-cyano-2-thioaryl) | |
| BRPI0922642A2 (pt) | "formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo" | |
| IL196876A0 (en) | 2-(heterocyclylbenzyl)pyridazinone derivatives | |
| ME02307B (me) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| IL187098A0 (en) | Derivatives of 4 - (2 - amino - 1 hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | |
| ZA200806985B (en) | Benzothiazole having histamine h3 receptor activity | |
| BRPI0716134A2 (pt) | tratamento de combinaÇço para diabetes mellitus | |
| BRPI0819595A2 (pt) | Derivados quirais de 2-(benzilsulfinil)-tiazol e derivados de 2-[(1h-pirazol-4-ilmetil)sulfinil]-tiazol, processos para a sua peparação, bem como seu uso como herbicidas e reguladores do crescimento de plantas. | |
| IL212186A0 (en) | Fungicidal heterocyclic compounds | |
| BRPI0815440A2 (pt) | 5-substituidos 2- (alcoximetil) furanos | |
| HK1116077A1 (en) | Roflumilast for the treatment of diabetes mellitus | |
| DK3567035T3 (da) | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer | |
| IL200956A (en) | 1– [2– (2,4 – dimethylphenylsulfonyl) –phenyl] piperazine for the treatment of pain | |
| DK2209778T3 (da) | Pyridin-2-yl-amino-1, 2, 4-thiadiazolderivater som glucokinase-aktivatorer til behandling af diabetes mellitus | |
| IL194549A0 (en) | 2-(pyridin-2-yl)-pyrimidines for use as fungicides | |
| SI2632921T1 (sl) | Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj | |
| IL200403A0 (en) | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide | |
| EP2135064A4 (en) | AMPEROMETRIC BIOSENSOR FOR THE DETERMINATION OF HISTAMINE | |
| EP2064202A4 (en) | NOVEL (5S) -5- [4- (5-CHLORO-PYRIDIN-2-YLOXY) -PIPERIDIN-1SULFONYLMETHYL] -5-METHYL-IMIDAZOLINE-2,4-DIONE CRYSTALLINE G FORM (1) AND THE INTERMEDIATES | |
| CL2007003002A1 (es) | Compuesto 3-[1-metil-1-(6-trifluorometil-piridin-3-il)-etilamino]-5-(3-trifluorometoxifenil)-1-(4-trifluorometil-fenil)-pirrolidin-2-ona; y uso para el tratamiento de un trastorno seleccionado de obesidad, esquizofrenia, abuso de sustancias o depende |